← FDA DRUG APPROVALS

FDA ANDA · ANDA205248

NATEGLINIDE

Sponsor: ZYDUS PHARMS

APPLICATION
ANDA205248
TYPE
ANDA
ORIGINAL APPROVAL
2016-07-06
LATEST ACTION
2024-08-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NATEGLINIDEPrescription
NATEGLINIDE 60MG · TABLET · ORAL
NATEGLINIDEPrescription
NATEGLINIDE 120MG · TABLET · ORAL

Approval history

2024-08-22Labeling · Supplement 6 · standardAP
2018-11-19Labeling · Supplement 2 · standardAP
2018-11-19Labeling · Supplement 1 · standardAP
2016-07-06UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →